What BathGenBio does

BathGenBio (Basgenbio Corporation, 주식회사 바스젠바이오) is a Seoul-based AI drug discovery and genomic biomarker company founded in 2018 that provides clinico-omics data analytics to pharmaceutical companies, biotech firms, academic medical centers, and Korean government health agencies. The company operates three core proprietary platforms: COCD (Clinico-Omics Cohort Database), an integrated multi-omics data layer built around an exclusive license to the K-Biobank (156,000 Korean subjects with up to 18 years longitudinal follow-up) plus UK Biobank (500K+), TCGA (10K+), and ADNI (2K+), totaling 730,000+ subjects; DEEPCT (DEEP learning-based Clinical Trial), a drug effect simulation platform that applies Mendelian randomization causal inference plus deep learning to identify drug targets, drug repurposing opportunities, optimal drug combinations, and responder/non-responder biomarkers; and TLBM (Time-Labeled BioMarker), a time-aware biomarker discovery framework that integrates polygenic risk scores with longitudinal data to predict disease onset timing and age-specific risk.

Revenue is generated through three primary streams: (1) technology licensing and out-licensing of biomarkers and drug targets (e.g., gastric cancer TLBM licensed to Gencuric; five colorectal cancer targets transferred to Yungjin Pharmaceutical) with upfront fees, milestones, and royalties; (2) fee-for-service and co-development contracts with pharmaceutical companies including Celltrion (10 joint R&D projects over 5 years plus equity investment), Daewoong Pharmaceutical, Donga ST, Yungjin Pharmaceutical, Allico Pharmaceutical, and Samjin Pharmaceutical; and (3) non-dilutive Korean government R&D funding, most notably a ₩3.6 billion Deep-tech Challenge Project award over three years for a digital-twin androgenetic alopecia drug program, alongside the 2024 창업성장기술개발사업 디딤돌 bridge program. Go-to-market is enterprise sales-led through direct engagement at international partnering conferences (BIO USA, BIO Japan, Global IR @JPM, BIO KOREA BIX), supported by peer-reviewed publications in Nature Scientific Reports and the Journal of Investigative Dermatology. The company holds 13+ registered patents (including a PCT international filing for core TLBM technology), T-4 grade technology evaluation, and operates under dual co-CEO leadership (Il-Tae Jang, MD and Ho Kim) with a Vice President/CFO hired in 2021 to lead IPO preparation.

Name

BathGenBio

Legal name

Basgenbio Corporation

Website

https://basgenbio.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

51–100 employees

Short description

BathGenBio is a Seoul-based AI drug discovery company that applies deep learning and Mendelian randomization to a 730,000+ subject multi-omics cohort database, selling biomarker licensing, drug target discovery, and co-development services to pharmaceutical and biotech companies in South Korea and internationally.

Ownership category

akta.pro rank

Product category

AI Drug Discovery Platform

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Bioinformatics, Multi-Omics Data Analysis & Interpretation Services (HLAGANAI)

akta.pro secondary industry

Translational Medicine & Biomarkers (HLAIALAF)

Keywords

• AI drug discovery
• Genomic biomarker analysis
• Drug target identification
• Precision medicine platform
• Multi-omics data analytics

Headquarters

HQ city

Mapo

HQ country

South Korea

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Technology Licensing & Transfer: Out-licensing of biomarkers (e.g., gastric cancer TLBM to Gencuric), drug targets (e.g., 5 colorectal cancer targets to Yungjin Pharmaceutical), and AI platform results to pharmaceutical companies. Revenue includes upfront payments, milestone payments, and royalties.
2. Co-development & Research Agreements: Fee-for-service and co-development contracts with pharmaceutical companies for drug target discovery, drug repurposing, combination therapy optimization, and responder biomarker identification using DEEPCT and TLBM platforms.
3. Government R&D Grants: Non-dilutive funding from Korean government programs including the Deep-tech Challenge Project (₩3.6B over 3 years), Startup Growth Technology Development (디딤돌), AI Voucher Support, and Global Technology Commercialization Support.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Core offering

BathGenBio (BasgenBio) provides an AI-powered drug development platform built on its COCD (Clinico-Omics Cohort Database) integrating K-Biobank with global biobanks. Its DEEPCT platform simulates clinical trial outcomes for drug efficacy, adverse reactions, optimal combinations, and responder identification, while its TLBM (Time-Labeled BioMarker) platform discovers time-aware biomarkers for disease risk prediction. The company licenses biomarkers and drug targets to pharmaceutical and biotech partners and runs co-development research agreements.

Product overview

Basgenbio is a clinical multi-omics AI drug development company offering an integrated platform centered on three core products: COCD (Clinico-Omics Cohort Database) platform for data infrastructure, DEEPCT (DEEP learning-based Clinical Trial) for drug effect simulation, and TLBM (Time-Labeled BioMarker) for time-aware disease prediction. These are supplemented by specialized sub-products including Drug Combination analysis, Drug Response biomarker discovery, and Drug Repurposing services. The COCD platform serves as the data foundation, integrating K-Biobank (156K+ Korean subjects) with global biobanks, while DEEPCT and TLBM provide the analytical capabilities for pharmaceutical partnerships and biomarker out-licensing.

Differentiator

Problem solved

Functional benefit

Products and services

• COCD Platform (Clinico-Omics Cohort Database) Integrated cohort database platform combining K-Biobank (156,000 Korean subjects) with UK Biobank (500K+), TCGA (10K+), and ADNI (2K+) that incorporates genomics, clinical, lifestyle, and multi-omics data to support disease prediction, diagnosis, biomarker discovery, and drug target research.
• DEEPCT (DEEP learning-based Clinical Trial) AI drug effect simulation platform that uses clinico-omics cohort data and Mendelian randomization methods to enable target discovery, drug-disease causal relationship identification, optimal drug combination recommendation, responder/non-responder biomarker identification, and drug repurposing without physical clinical trials.
• TLBM (Time-Labeled BioMarker) Biomarker discovery platform incorporating time-factor data to predict disease onset timing and age-specific risk trajectories, integrating genetic risk scores with longitudinal health trajectory data to enable disease prediction, diagnosis, and prognosis.
• Drug Combination (COMBI FINDER) Drug combination optimization tool analyzing prescription data, Mendelian randomization, network analysis, and AI to recommend optimal fixed-dose combination structures from 2-drug to N-drug combinations.
• Drug Response Biomarker Algorithm development service for predicting drug responders vs. non-responders, identifying biomarkers that classify treatment response for specific drug categories to enable personalized medicine.
• Drug Repurposing

Quantifiable outcome

• 17x higher gastric cancer risk for high-risk group vs. normal group identified by TLBM biomarker BAS-GC-0001
• +4 more outcomes

Named customers10 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature5 records

Partnerships

20 partnerships are on record, tiered core and minor.

• Yonsei Medical Center (연세의료원)coreStrategic or Co-development PartnerExclusive technology transfer and co-development agreement signed May 2021 for Korean genomic cohort data (15.6万 subjects, ~₩77B R&D investment). BasgenBio acquired exclusive rights to K-Biobank and jointly conducts genomic cohort construction. ₩2.5B paid-in capital investment from Yonsei产学研合作단 in June 2021.
• Ewha Medical Center (이화의료원)coreStrategic or Co-development PartnerMOU signed July 2021 for research linking genomic cohort data with EMR records. Ewha provides additional genomic cohort data and clinical records to expand BasgenBio's multi-omics dataset.
• Korea University Medical Center (고려대학교의료원)coreStrategic or Co-development PartnerMOU signed August 2021 for AI-based precision medicine convergence platform development. Korea University contributes approximately 10,000 cancer patient genomic data — described as unique in Asia.
• CelltrioncoreStrategic or Co-development PartnerComprehensive biomarker development partnership with equity investment signed May 2023. Plans 10 joint R&D projects over 5 years covering genomic analysis, biomarker discovery, target identification, candidate screening, and clinical trial design. Celltrion made a strategic equity investment alongside the partnership.
• Yungjin Pharmaceutical (영진약품)coreStrategic or Co-development PartnerTechnology transfer agreement for 5 novel colorectal cancer targets and effective substances, signed September 2024. Also signed March 2024 MOU for KL1333 indication expansion (mitochondrial disease drug). Yungjin has a strategic interest in KL1333 (in-licensed from Abliva, entering Phase 2/3).
• Daewoong Pharmaceutical (대웅제약)coreStrategic or Co-development PartnerOpen innovation collaboration selected for 2024 Korea Civil Collaboration program. Project focuses on anticancer drug combination optimization and efficacy simulation using DEEPCT platform, with ₩50M government support. Jointly won Grand Prize in the demand-based category of the 2024 민관협력 오픈이노베이션 program.
• Donga ST (동아에스티)minorStrategic or Co-development PartnerBusiness collaboration agreement signed April 2024 for indication research of anticancer drug candidates using DEEPCT platform to identify and validate additional indications.
• Allico Pharmaceutical (알리코제약)minorStrategic or Co-development PartnerMOU signed September 2022 for combination drug development. BasgenBio applies DEEPCT to identify optimal drug combinations; Allico validates and commercializes the combinations.
• Samjin Pharmaceutical (삼진제약)minorStrategic or Co-development PartnerAI new drug development MOU signed November 2022 for target discovery and efficacy evaluation of new drug candidates using BasgenBio's genomic cohort data and AI platform.
• Hanyang University Rheumatism Research Institute (한양대학교류마티즘연구소)coreStrategic or Co-development PartnerMOU signed March 2024 to leverage Korea's largest rheumatic arthritis cohort (since 2001) plus SLE cohort data (since 1998) for drug target discovery using DEEPCT in rheumatoid arthritis, SLE, and ankylosing spondylitis.
• Gencuric (젠큐릭스)coreOEM/ Whitelabel/ Licensing PartnerTechnology transfer agreement signed September 2022 for gastric cancer TLBM biomarker. First commercial out-licensing of BasgenBio's time-labeled biomarker technology for molecular diagnostic product development.
• KSB Tugen (케이에스비튜젠)minorStrategic or Co-development PartnerGlobal licensing partnership for sarcopenia drug candidate KSB-10301. BasgenBio validated the target and drug effects using DEEPCT, demonstrating superiority over competing drugs. KSB-10301 entered Phase 2 clinical trial in November 2024.
• Seoul Metropolitan Government / SBA (서울산업진흥원)minorGTM or Marketing PartnerSelected for Weconomy Startup Challenge 2024 as one of 15 promising startups from 187 applicants, collaborating with 8 large companies in Magok industrial complex including LG Sciencepark, Daewoong Pharmaceutical, and others.
• 3-BIGS (쓰리빅스)minorStrategic or Co-development PartnerAI bio-bigdata commercialization MOU signed 2023 for peptide drug efficacy validation using BasgenBio's genomic cohort data and AI analysis platform.
• Hancomcarelink (한컴케어링크)minorStrategic or Co-development PartnerAI bio-bigdata commercialization MOU signed 2023 for healthcare data collaboration.
• KTminorOthersSelected for KT's Hyperscale AI Computing (HAC) GPU cloud support program. Received large-scale GPU infrastructure at no cost for AI model training and genomic data analysis, saving approximately ₩1 billion in infrastructure costs. Support extended to February 2024.
• Korea Government — Deep-tech Challenge ProjectcoreOthersSelected for Korea's Deep-tech Challenge Project receiving up to ₩3.6 billion (~$2.4M) in government R&D funding over 3 years for digital-twin androgenetic alopecia drug program. Collaborates with Yonsei University and Dankook University for clinical and omics dataset mining.
• Korea Ministry of SMEs and Startups — 2024 창업성장기술개발사업minorOthersSelected for '2024 3rd 디딤돌' Startup Growth Technology Development program. Receives up to ₩120 million in technology development funding over 1 year.
• SeoulBioHub / Invest Seoul (서울바이오허브/인베스트서울)minorGTM or Marketing PartnerBasgenBio was admitted to SeoulBioHub startup cluster and received support from Invest Seoul for participation in global BIO conferences and IR activities.
• Yonsei University Graduate School of Public Health (연세대학교 보건대학원)coreStrategic or Co-development PartnerLong-standing research collaboration since 2018. Professor Ji Sun-ha has led cohort data collection since 2005. Joint research published in Korean Journal of Epidemiology (Epidemiology and Health) on bilirubin-ischemic stroke causal relationship.

Scale indicators12 records

Recent moves7 records

Direct peers

• Recursion Pharmaceuticals: AI-driven drug discovery company combining high-throughput biology with machine learning. Comparable to BasgenBio in using AI to accelerate pharma R&D, though Recursion focuses on phenotypic screening rather than genomic cohort analysis.
• Insilico Medicine: AI drug discovery platform using generative AI and multi-omics data for target identification and drug design. Directly comparable to BasgenBio's DEEPCT platform for AI-driven target discovery and drug repurposing.
• Exscientia: AI-driven precision medicine company focused on patient selection and drug design. Directly comparable to BasgenBio's drug response biomarker and target discovery offerings for pharmaceutical partners.
• Standigm: Korean AI drug discovery company using proprietary AI workflows for target identification, lead optimization, and drug repurposing. Closest Korean peer to BasgenBio, operating in the same domestic pharma ecosystem with similar GTM motion.
• Syntekabio: Korean AI drug discovery company using deep learning for novel drug development and biomarker discovery. Comparable as a domestic peer in the Korean AI biotech space with pharma partnership model.

Broad incumbents

• Schrödinger: Established computational chemistry and molecular simulation platform serving pharma R&D. Comparable as a pharma-facing AI/ML drug discovery company, but Schrödinger's focus is physics-based simulation rather than genomic cohort analysis.
• Tempus Labs: Large-scale clinical and genomic data company enabling precision medicine. Comparable to BasgenBio's COCD platform in building multi-modal clinico-omics datasets, but Tempus operates at much larger scale in oncology-focused US market.

Emerging players

• Owkin: AI biotech company combining multi-omics data with federated learning for drug discovery and clinical trial optimization. Comparable in using AI on multi-omics cohorts to support pharma R&D decisions, with similar biomarker discovery positioning.
• XtalPi: AI-driven drug discovery company combining quantum physics, AI, and cloud computing for pharmaceutical R&D. Comparable as an AI-platform-for-pharma peer, though XtalPi focuses on molecular design rather than genomic biomarker discovery.
• Arontier: Korean AI-driven drug discovery company focused on new drug candidate identification. Comparable as a Korean peer in AI drug discovery with similar pharmaceutical partnership business model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/BASGENBIO

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BathGenBio